Ustekinumab

Generic Name
Ustekinumab
Brand Names
Stelara, Pyzchiva, Uzpruvo, Wezenla, Steqeyma, Otulfi, Fymskina, Eksunbi
Drug Type
Biotech
Chemical Formula
-
CAS Number
815610-63-0
Unique Ingredient Identifier
FU77B4U5Z0
Background

Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMAR...

Indication

Ustekinumab is indicated for the management of moderate to severe plaque psoriasis in patients 6 years of age and older who are candidates for phototherapy or systemic therapy. In adult patients, it is also indicated for the management of active psoriatic arthritis (PsA) alone or in combination with methotrexate, moderately to severely active Crohn’s disease...

Associated Conditions
Severe Plaque psoriasis, Ulcerative Colitis, Active Severe, Active Psoriatic arthritis, Moderate Plaque psoriasis, Moderate Ulcerative colitis, Moderate, active Crohn´s Disease, Severe, active Crohn´s Disease
Associated Therapies
-
Clinical Trials
Related News

Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: Ustekinumab
Other: Placebo
First Posted Date
2013-03-07
Last Posted Date
2018-03-14
Lead Sponsor
Rockefeller University
Target Recruit Count
32
Registration Number
NCT01806662
Locations
🇺🇸

Rockefeller University, New York, New York, United States

Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease

First Posted Date
2012-10-24
Last Posted Date
2020-03-04
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
54
Registration Number
NCT01713400
Locations
🇺🇸

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

First Posted Date
2012-10-17
Last Posted Date
2020-01-03
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
1881
Registration Number
NCT01708629
Locations
🇷🇺

Research Site, St. Petersburg, Russian Federation

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

First Posted Date
2012-10-17
Last Posted Date
2020-01-06
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
1831
Registration Number
NCT01708603
Locations
🇪🇸

Research Site, Madrid, Spain

Swiss Dermatology Network of Targeted Therapies (SDNTT)

First Posted Date
2012-10-15
Last Posted Date
2024-11-29
Lead Sponsor
Swiss Dermatology Network for Targeted Therapies
Target Recruit Count
1121
Registration Number
NCT01706692
Locations
🇨🇭

Aarau Cantonal Hospital, Aarau, Switzerland

🇨🇭

Inselspital - Bern University Hospital, Bern, Switzerland

🇨🇭

Basel University Hospital, Basel, Switzerland

and more 3 locations

A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa

Phase 2
Completed
Conditions
Hidradenitis Suppurativa
Interventions
Drug: Ustekinumab
First Posted Date
2012-10-11
Last Posted Date
2024-04-18
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
20
Registration Number
NCT01704534
Locations
🇳🇱

University Medical Centre Groningen, Groningen, Netherlands

Ustekinumab for Active Sight-Threatening Uveitis

Phase 1
Withdrawn
Conditions
Uveitis
First Posted Date
2012-07-20
Last Posted Date
2019-12-05
Lead Sponsor
National Eye Institute (NEI)
Registration Number
NCT01647152

A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis

First Posted Date
2012-03-20
Last Posted Date
2012-07-18
Lead Sponsor
Paul Steven Yamauchi, MD, PhD
Target Recruit Count
30
Registration Number
NCT01558310
Locations
🇺🇸

Clinical Science Institute, Santa Monica, California, United States

The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment

Phase 4
Completed
Conditions
Psoriasis
Interventions
Drug: Ustekinumab
First Posted Date
2012-01-18
Last Posted Date
2016-02-12
Lead Sponsor
University of California, San Francisco
Target Recruit Count
36
Registration Number
NCT01511315
Locations
🇺🇸

UCSF Psoriasis and Skin Treatment Center, San Francisco, California, United States

Ustekinumab for the Treatment of Patients With Active Ankylosing Spondylitis

Phase 2
Completed
Conditions
Ankylosing Spondylitis
Interventions
Drug: Ustekinumab
First Posted Date
2011-04-07
Last Posted Date
2013-06-04
Lead Sponsor
Charite University, Berlin, Germany
Target Recruit Count
22
Registration Number
NCT01330901
Locations
🇩🇪

Department of Rheumatology, Charité - Campus Benjamin Franklin, Berlin, Germany

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy